

Review

From Herb to Hope: A Systematic Exploration of Medicinal Plants' Role in Cancer Therapy

Sahar S. Alghamdi^{1,2,3}✉, Ruya Alshkrh¹, Afrah E. Mohammed^{4,5}, Shuroug A. Alowais^{1,2,3}

1. King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia.
2. King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia.
3. Ministry of National Guard Health Affairs (MNGHA), Riyadh, Saudi Arabia.
4. Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
5. Microbiology and Immunology Unit, Natural and Health Sciences Research Center, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.

✉ Corresponding author: Dr. Sahar Alghamdi, ghamdisa@ksau-hs.edu.sa.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>). See <https://ivyspring.com/terms> for full terms and conditions.

Received: 2025.04.01; Accepted: 2025.07.08; Published: 2025.09.27

Abstract

Medicinal plants play a critical role in drug development, serving as a valuable source of bioactive compounds. Cancer, characterized by uncontrolled cell proliferation, presents significant challenges in treatment due to its multifaceted nature. This study aims to evaluate the anticancer potentials of selected medicinal plants specifically focusing on *in vitro* and *in vivo* studies that evaluate therapeutic implications for cancer treatment. A systematic review was conducted to assess both *in vitro* and *in vivo* studies involving selected medicinal plants: *Saussurea costus*, *Lepidium sativum*, *Rhus tripartite*, *Pyrus communis*, *Chenopodium murale*, *Erucaria hispanica*, *Trigonella hamosa*, *Argemone ochroleuca*, and *Galium odoratum*. The review involved analyzing cancer cell lines, plant parts used, extraction methods, and mechanisms of action reported in the literature. A total of sixty-nine articles were identified that investigated the anticancer properties of the selected plants. Notably, *S. costus*, *L. sativum*, and *R. tripartite* exhibited significant anticancer potential. In contrast, *P. communis*, *C. murale*, *E. hispanica*, *T. hamosa*, *A. ochroleuca*, and *G. odoratum* had limited studies available. The predominant mechanism of action identified for the anticancer activity was the induction of apoptosis. The findings indicate that these medicinal herbs possess promising therapeutic potential as anti-cancer agents. However, further research is warranted for *P. communis*, *C. murale*, *E. hispanica*, *T. hamosa*, *A. ochroleuca*, and *G. odoratum* to enhance understanding of their anticancer activities and explore their full therapeutic capabilities.

Keywords: *Saussurea costus*; *Lepidium sativum*; *Rhus tripartite*; *Pyrus communis*; *Chenopodium murale*; *Erucaria hispanica*; *Trigonella hamosa*; *Argemone ochroleuca*; *Galium odoratum*; anticancer; *in vitro*; *in vivo*

1. Introduction

Medicinal plants have played an important role in the discovery of innovative treatments for a variety of diseases. Compounds derived from many herbal plants have demonstrated important therapeutic effects on human pathologies [1]. As a result, medicinal plants are increasingly recognized as a potential source for identifying candidate drugs, particularly in the search for cancer therapies and in efforts to minimize cancer cell resistance to treatment.

Cancer is one of the diseases that has been an obstacle in the scientific and medical fields due to its complex biological nature. The use of plants as potential cancer therapies has been a subject of

interest throughout history [2]. Globally, approximately 20 million new cancer cases and 9 million cancer-related deaths were reported in 2022 [3]. The treatment of these diseases is becoming more challenging due to resistance to current treatments. In addition to resistance, the side effects of the cancer therapies impact the patient's quality of life. Thus, it is a global concern, as it can hinder treatment and has an impact on the prognosis of the disease, prompting researchers to pursue novel pharmacological solutions.

In recent years, there has been an ongoing quest for effective drugs as a preventive therapies for

cancer, and to overcome the resistance issue [4]. In this context, medicinal plants are being studied as possible anticancer treatments. Recent findings on medicinal plants (*Saussurea costus*, *Lepidium sativum*, *Rhus tripartite*, *Pyrus communis*, *Chenopodium murale*, *Erucaria hispanica*, *Trigonella hamosa*, *Argemone ochroleuca*, and *Galium odoratum*) have increased the scientific interest in their bioactive compounds, particularly anticancer properties [5–13]. Traditionally, these plants have been used for a variety of purposes, including antimicrobial, antioxidant, and anticancer applications. They contain a variety of secondary metabolites, such as polyphenols, flavonoids, steroids, which enhance their ability to induce the cancer cell death via different mechanisms.

The main aim of this systematic review is to assemble all current studies that explore and analyze the anticancer activity of the extracted parts of the selected medicinal plants in both *in vitro* and *in vivo* models.

2. Methods

2.1. Research questions

This systematic review focuses on the analysis of the anticancer activity for the extracts or isolated compounds of selected plants (*Saussurea costus*, *Lepidium sativum*, *Rhus tripartite*, *Pyrus communis*, *Chenopodium murale*, *Erucaria hispanica*, *Trigonella hamosa*, *Argemone ochroleuca*, and *Galium odoratum*) and their effects on *in vitro* and *in vivo* models, following the Preferred Reporting Items for Systematic Reviews

and Meta-Analyses (PRISMA) guidelines. We included studies published within the past 24 years (2000–2024) to ensure adequate representation of historical and recent research findings regarding the selected medicinal plants (Figure 1).

2.2. Data sources

Google Scholar was utilized as a database to identify the studies that investigate the anticancer properties of the selected medicinal plants. As a search strategy, to conduct a comprehensive search, we utilized certain keywords and specific phrases, it involves "*Saussurea costus*" AND ("anticancer" OR "cytotoxic") AND ("*in vitro*" OR "*in vivo*"), "*Lepidium sativum*" AND ("anticancer" OR "cytotoxic") AND ("*in vitro*" OR "*in vivo*"), and so forth for each plant. The search is limited by the filter to include the articles that are published between 01/01/2000 to 01/08/2024 in English.

2.3. Inclusion criteria

Selected articles were required to investigate the potential anticancer effects for the chosen medicinal plants using *in vitro* or *in vivo* models, with plant extracts or isolated compounds tested against cancer cell lines or tumor-induced animal models.

2.4. Exclusion criteria

Articles were excluded if they did not evaluate anticancer activity or did not involve cancer cell lines or tumor models. Additionally, non-English articles, clinical trials, and non-original studies (e.g., systematic reviews or meta-analysis) were excluded.




Figure 1. The systematic review approach and scope. A systematic review focused on the anticancer activity of selected medicinal plants, including original studies such as *in vitro* and *in vivo*. Data selection was based on the study's title, language, and relevance objectives, with data sources determined by keywords and filters. Data extracted includes cancer cell type, extraction methods, IC₅₀ values, and proposed mechanism of action.




Figure 2. Flow chart illustrating the study selection process: A total of 15,018 records were identified, of which 14,950 were excluded due to irrelevant research questions or different plant species. After screening 72 records, 2 were excluded due to language barriers and one was retracted resulting in 69 studies included in the final analysis.

2.5. Study selection

The screening of the preselected articles, using the described search strategy, was conducted by a single author and initially based on title and abstract review (Figure 2). Duplicates, studies irrelevant to the research question, and those investigating different plant species were excluded. Subsequently, the studies that are written with different languages other than English were eliminated. The final selection of the eligible studies was carried out by a single author.

2.6. Data extraction

Data extraction was carried out by a single author for all included articles. The extracted information encompassed several key aspects: the type of cancer cells treated with the plant extracts, the specific plant name, the part of the plant utilized in the study, the extraction methods and solvents employed by researchers, and the results, including values for IC₅₀. Additionally, any proposed mechanisms of action suggested by the studies were recorded.

3. Results

To assess their anticancer activity and mechanism of action, a comprehensive review of *in vitro* and *in vivo* studies on nine plants—*Saussurea costus*, *Lepidium sativum*, *Rhus tripartite*, *Pyrus communis*, *Chenopodium murale*, *Erucaria hispanica*, *Trigonella hamosa*, *Argemone ochroleuca*, and *Galium odoratum*—was conducted. The selected medicinal plants have been investigated for their cytotoxic

potential against a variety of cancers, including acute myeloid leukemia, breast cancer, lung cancer, colon cancer, tongue squamous cell carcinoma, colorectal cancer, liver cancer, prostate cancer, melanoma, cervical cancer, neuroblastoma, adenocarcinoma, ovarian cancer, esophageal cancer, gastric cancer, and skin cancer. Following a thorough examination for sixty-one *in vitro* and *in vivo* studies, the findings revealed that the *S. costus*, *L. sativum*, *R. tripartite*, *C. murale*, *P. communis*, *E. hispanica*, *T. hamosa* were investigated for their cytotoxic activity. No studies were found evaluating the anticancer properties of *A. ochroleuca* and *G. odoratum*'s anticancer properties (Table 1).

The proposed mechanism of action is mostly related to generation of reactive oxygen species (ROS) and induction of apoptosis.

Table 1. Comprehensive overview of anticancer studies on selected medicinal plants.

Plant Name	Number of Studies Identified	Types of Experimental Approach
<i>S. costus</i>	Forty studies	<i>In vitro</i> , and <i>in vivo</i>
<i>L. sativum</i>	Fifteen studies	<i>In vitro</i> , and <i>in vivo</i>
<i>R. tripartite</i>	Four studies	<i>In vitro</i>
<i>P. communis</i>	Two studies	<i>In vitro</i>
<i>C. murale</i>	One study	<i>In vitro</i>
<i>E. hispanica</i>	One study	<i>In vitro</i>
<i>T. hamosa</i>	One study	<i>In vitro</i>
<i>A. ochroleuca</i>	No study	Not applicable
<i>G. odoratum</i> 's	No study	Not applicable

*No study: No reported studies available for these plants.

3.1. *Saussurea costus*

S. costus was the most extensively studied plant across diverse types of cancer, including breast cancer (MCF-7, MDA-MB-231, SK-BR-3, MDA-MB-453), colon cancer (HTC116, Caco2, LS174T, HT-15, HT-29), liver cancer (HepG-2, HuH-7, PLC/PRF/5, SMMC-7721), lung cancer (A549, SK-MES-1), gastric cancer (AGS), central nervous system (CNS) cancer (XF498, IMR-32, SH-SY5Y, Rat B103), prostate cancer (PC-3, LNCaP, DU145), leukemia (HL-60, Jurkat E6-1, THP-1), cervical cancer (HeLa), esophageal cancer (Eca109, KYSE150), ovarian cancer (SK-OV-3, OVCAR3), soft tissue sarcoma (SW-872, SW-982, TE-671) [14–33].

In vitro studies utilized different parts of *S. costus*; however, root was the most utilized part for the most cancer types, while a few studies tested leaves and fruits of *S. costus* for breast (MCF-7), colon (CaCo-2), liver cancer (HepG2) [22,25,29,34–38]. Other studies investigated isolated compounds, namely

costunolide and dehydrocostuslactone [14–16,18,20,21,32,39–41].

Breast cancer was the most studied cancer type, with MCF-7 as the predominant cell line, in addition to MDA-MB-231, SK-BR-3, and MDA-MB-453, demonstrating the versatility of extracts and solvents. In a study conducted by Peng et al. (2013), the roots were extracted using liquid-liquid extraction with methanol and ethyl acetate and tested on MCF-7 cell lines, revealing IC₅₀ values ranging from 1.7 to 6.1 µg/mL [28]. Similar findings were reported by Bhushan et al. (2023), where liquid-liquid extraction was applied to root extracts and tested on the MDA-MB-231 cell line using additional solvents such as hexane, chloroform, ethanol, and butanol [37]. A similar trend was observed, where hexane and chloroform showed IC₅₀ values of 5.3–12.18 µg/mL, whereas ethanol and butanol exhibited higher IC₅₀ values, ranging from 20 to >100 µg/mL. Comparable results were observed for other plant parts, including leaves and fruits, as summarized in Table 2.

Table 2. Comprehensive analysis of *in vitro* anticancer studies on *Saussurea costus*: cell lines, extracts, and mechanisms of action.

Cancer Type	Part Used	Extraction Method	IC ₅₀	Proposed Mechanisms	Results Description	References
Breast Cancer						
MCF-7	Roots	Ethanol by maceration liquid-liquid extraction	10 µg/mL	Inhibition of NF-κB and MMP-9	Decrease the cellular proliferation and control the cancer invasiveness	[34]
		Ethanol	20 µg/mL	Apoptosis regulations	Decrease cellular proliferation	[44]
		Methanol by soxhlet extraction + MgO nanoparticles	80 µg/mL	Apoptosis by induction of ROS	Decrease cellular proliferation	[43]
		Methanol by maceration	122.5 µg/mL	Apoptosis regulations and cell cycle effects	Decrease cellular proliferation	[78]
		Water, Methanol by sonication, Ethyl Acetate by liquid-liquid extraction	1.7–6.1 µg/mL	Not determined	Decrease cellular proliferation	[28]
	Leaves	Methanol, Hexane, Chloroform, Ethyl Acetate, n-Butanol by liquid-liquid extraction	0.54 - 25.5 µg/mL	Apoptosis regulations and caspase activity	Decrease cellular proliferation	[30]
	Fruits	Aqueous extracts by maceration	0.5 mg/mL	Inhibition of NF-κB and MMP-7	Decrease cellular proliferation,	[84]
	Powder	Supercritical Carbon Dioxide Extraction	0.46 µg/mL	Not determined	Decrease cellular proliferation,	[42]
	Not applicable	Single isolated metabolite (costunolide)	30.16 µM	Intrinsic apoptosis and mitophagy activation	Decrease cellular proliferation,	[39]
MDA-MB-231	Roots	Palladium nanoparticle with aqueous extracts	26.7 - 114.6 µg/mL	Not determined	Decrease cellular proliferation,	[14]
		Ethanol by maceration, Hexane, Chloroform, n-Butanol by liquid-liquid extraction	5.353 - >100 µg/mL	Not determined	Decrease cellular proliferation,	[37]
		Ethanol by maceration liquid-liquid extraction	Ethanol extracts did not inhibit 50% of cells	Inhibition of NF-κB and MMP-9	Decrease the cellular proliferation and control the cancer invasiveness	[34]
		Ethanol by sonication	50 µg/mL	TNFα and NF-κB inhibition	Decrease the cellular proliferation and control the cancer invasiveness	[47]
	Not applicable	Hexane by soxhlet for 72 hours	0.56 - 0.88 µM/ml	Not determined	Decrease cellular proliferation	[26]
SK-BR-3	Not applicable	Single isolated metabolite (dehydrocostuslactone)	21.5 µM	Not determined	Decrease cellular proliferation	[15]
		Single isolated metabolite (costunolide)	12.76 µM	Intrinsic apoptosis and mitophagy activation	Decrease cellular proliferation	[39]
	Not applicable	Single isolated metabolite (dehydrocostuslactone)	25.6 µM	Not determined	Decrease cellular proliferation	[15]
MDA-MB-453	Not applicable	Single isolated metabolite (dehydrocostuslactone)	43.2 µM	Not determined	Decrease cellular proliferation	[15]
Colon Cancer						

Cancer Type	Part Used	Extraction Method	IC ₅₀	Proposed Mechanisms	Results Description	References
HCT-116	Roots	Ethanol by maceration, Hexane, Chloroform, n-Butanol (liquid-liquid extraction)	4.717->100 µg/mL	Not determined	Decrease cellular proliferation	[37]
		Ethanol and Hexane by cold percolation	82.64 µg/mL	Apoptosis regulation and angiogenesis reduction	Decrease cellular proliferation	[35]
		Hexane by sonication	Hexane extracts did not show effect on the viability	Cell Cycle Arrest, Gene Expression Changes (BCL2, CASP3, TP53, BAX), Mitochondrial Dysfunction	The extracts did not affect the cellular viability (reduced cells ~ 20%, however it induced apoptosis)	[21]
	Leaves	Methanol, Hexane, Chloroform, Ethyl acetate, n-Butanol by liquid-liquid extraction	0.4-24.9 µg/mL	Apoptosis regulation and caspases activities modulation	Decrease cellular proliferation	[30]
	Powder	Supercritical Carbon Dioxide Extraction	0.44µg/mL	Not determined	Decrease cellular proliferation	[42]
	Not determined	Palladium nanoparticles	7.8 - 82.5 µg/mL	Not determined	Decrease cellular proliferation, nanoparticles formulation enhances the anticancer activity	[14]
CaCo-2	Fruits	Aqueous extracts by maceration	1 mg/mL	Apoptosis	Decrease cellular proliferation	[84]
HCT-15	Roots	Methanol	1.16 - 1.55 µM	Not applicable	Decrease cellular proliferation	[46]
LS174T	Not applicable	Bilosome-based on single isolated metabolites (costunolide)	6.20 - 15.78 µM	Apoptosis regulation, caspase activity	Decrease cellular proliferation	[21]
HT-29	Roots	Hexane by sonication	The hexane extracts did not show effect on the viability	Cell Cycle Arrest, Gene Expression Changes (BCL2, CASP3, TP53, BAX), Mitochondrial Dysfunction,	The extracts did not affect the cellular viability (reduced cells ~ 20%, however it induced apoptosis)	[21]
Liver Cancer						
HepG2	Roots	Chloroform, n-Butanol, Ethyl Acetate by soxhlet apparatus	56.76 µg/mL	Apoptosis regulation, caspase activity	Decrease cellular proliferation	[36]
		Ethanol, Hexane by cold percolation	154.30 µg/mL	Apoptosis and reduction of the angiogenesis	Decrease cellular proliferation	[35]
		Aqueous, Ethanol, Hydro-ethanol	1.10 - 3.5 mg/mL	Apoptosis regulation	Decrease cellular proliferation	[85]
		Methanol, Water, Petroleum Ether, n-Butanol, Acetone, Ethyl Acetate	20 mM	Apoptosis regulation and reactive oxygen species induction	Decrease cellular proliferation	[86]
		Chloroform, n-Butanol, Ethyl Acetate by soxhlet apparatus	56.76 µg/mL	Apoptosis regulation, caspase activity	Decrease cellular proliferation	[36]
		Hexane, Ethyl Acetate, n-Butanol, Water	5 - 20 µg/mL	Autophagy inhibition	Decrease cellular proliferation	[87]
		Methanol, Water, Petroleum Ether, n-Butanol, Acetone, Ethyl Acetate	20 mM	Apoptosis regulation and reactive oxygen species induction	Decrease cellular proliferation	[86]
	Leaves	Methanol, Hexane, Chloroform, Ethyl Acetate, n-Butanol by liquid-liquid extraction	0.5-33.2 µg/mL	Apoptosis regulation, caspase activity	Decrease cellular proliferation	[30]
	Powder	Supercritical Carbon Dioxide	0.74 µg/mL	Not determined	Decrease cellular proliferation	[42]
	Not applicable	Single isolated metabolite (dehydrocostuslactone)	16.7 µM	Intrinsic apoptosis, ER stress induction, MAPK activation, Phosphorylation signaling	Decrease cellular proliferation	[18]
PLC/PRF/5	Not applicable	Single isolated metabolite (dehydrocostuslactone)	18.8 µM	Intrinsic apoptosis, ER stress induction, MAPK activation, Phosphorylation signaling; Apoptosis	Decrease cellular proliferation	[18]
SMMC-7721	Roots	Methanol, Water, Petroleum Ether, n-Butanol, Acetone, Ethyl Acetate	20 µM	Apoptosis regulation and reactive oxygen species induction	Decrease cellular proliferation	[86]
Lung Cancer						
A-549	Roots	Ethanol by maceration, Hexane, Chloroform, n-Butanol by liquid-liquid extraction	11.875->100 µg/mL	Not determined	Decrease cellular proliferation	[37]
		Ethanol, Chloroform, Ethyl Acetate, n-Butanol	38.5->100 µg/m	Not determined	Decrease cellular proliferation	[23]
		Methanol	1.64-2.97 µM	Not determined	Decrease cellular proliferation	[46]
		Chloroform, Ethanol by soxhlet apparatus	37.90 µg/ml	Not determined	Decrease cellular proliferation	[17]
		Hexane by soxhlet apparatus for 72 hours	3.9 - 7.4 µM/ml	Not determined	Decrease cellular proliferation	[26]
	Not	Single isolated metabolites	6.1 -13.4 µM	Gene expression activity (BCL2, P53, BAX),	Decrease cellular proliferation	[40]

Cancer Type	Part Used	Extraction Method	IC ₅₀	Proposed Mechanisms	Results Description	References
	applicable	(costunolide)		suppression of the TNF α and NF- κ B		
SK-MES-1	Not applicable	Single isolated metabolites (costunolide)	~50–60 μ M	Cell cycle affects, Apoptosis regulation, Protein expression changes (p53, p27, p21)	Decrease cellular proliferation	[20]
Neuroblastoma						
IMR-32	Roots	Hexane by soxhlet apparatus for 72 hours	4.1 – 4.2 μ M/mL;	Not determined	Decrease cellular proliferation	[26]
	Not applicable	Two isolated metabolites (dehydrocostus lactone and costunolide)	1.26–6.52 μ M	Apoptosis regulation and reduction the invasion of the cell	Decrease cellular proliferation and control the cancer invasiveness	[32]
XF498	Roots;	Methanol;	0.43 – 1.70 μ M;	Not determined	Decrease cellular proliferation	[46]
SH-SY5Y	Roots	Ethanol	15 μ g/mL	Apoptosis regulation, caspase activity, gene expression activity (BCL2, P53, BAX), changes in protein expression (AKT and GSK-3 β activity)	Decrease cellular proliferation	[29]
B103	Roots	Ethanol	20 μ g/mL	Apoptosis regulation, caspase activity, gene expression activity (BCL2, P53, BAX), changes in protein expression (AKT and GSK-3 β activity)	Decrease cellular proliferation	[29]
LA-N-1	Not applicable	Two isolated metabolites (dehydrocostus lactone and costunolide)	1.26–6.52 μ M	Apoptosis regulation and reduction the invasion of the cell	Decrease cellular proliferation and control the cancer invasiveness	[32]
SK-N-SH	Not applicable	Two isolated metabolites (dehydrocostus lactone and costunolide)	1.26–6.52 μ M	Apoptosis regulation and reduction the invasion of the cell	Decrease cellular proliferation and control the cancer invasiveness	[32]
Prostate Cancer						
DU-145	Roots	Hexane by soxhlet apparatus for 72 hours	0.64 - 3.4 μ M/ml	Not determined	Decrease cellular proliferation	[26]
		Hexane by sonication	Hexane extracts did not affect the viability	Apoptosis regulation, caspase activity, gene expression activity (BCL2, P53, BAX)	Decrease cellular proliferation	[21]
			Hexane did not affect the viability of the cell	Changes in TIMP, MMP-9 expression, inhibition of cell migration	The extracts did not affect the cellular viability (reduced cells ~ 20%, however it induced apoptosis and inhibits the cell migration)	[38]
LNCaP	Roots	Ethanol	50 μ g/ml	Apoptosis regulation, gene expression activity (BCL2, P53, BAX), effects on androgen signaling, decrease cell migration, effects on the autophagy activity	Decrease cellular proliferation	[33]
		Hexane by sonication	Hexane extracts did not affect the viability	Apoptosis regulation, caspase activity, gene expression activity (BCL2, P53, BAX)	Decrease cellular proliferation	[21]
PC-3	Roots	Ethanol by maceration, Hexane, Chloroform, n-Butanol (liquid-liquid extraction)	3.37 – >100 μ g/mL	Not determined	Decrease cellular proliferation	[38]
TRAMP-C	Roots	Hexane by sonication	Hexane did not affect the viability of the cell	Changes in TIMP, MMP-9 expression, inhibition of cell migration	The extracts did not affect the cellular viability (reduced cells ~ 20%, however it induced apoptosis and inhibits the cell migration)	[38]
Gastric Cancer						
AGS	Roots	Ethanol extracts by sonication followed by freeze-drying	100 μ g/mL	Apoptosis regulation, caspase activity, gene expression activity (BCL2, P53, BAX), cell cycle effects	Decrease cellular proliferation	[45]
		Ethanol extracts by sonication followed by freeze-drying	79 μ g/mL	Apoptosis regulation, caspase activity, gene expression activity (BCL2, P53, BAX), cell cycle effects	Decrease cellular proliferation	[31]
	Not applicable	Single isolated metabolites (costunolide)	4.5 μ M	Not determined	Decrease cellular proliferation	[41]
Leukemia						
CCRF-CEM	Roots	Methanol; Petroleum Ether, Methanol by soxhlet apparatus	Not determined	Apoptosis regulation, cell cycle effects, and decrease the proteins expression of the multidrug resistance	Decrease cellular proliferation	[22]
HL-60	Roots	Partitioning into Ethyl Acetate, Water, n-Butanol	5 mM	Apoptosis and NF- κ B inhibition	Decrease cellular proliferation	[25]
U937	Roots	Methanol	Not determined	Apoptosis and Cell cycle effects	Decrease cellular proliferation	[46]
Cervical Cancer						
SIHA	Roots	Hexane by soxhlet apparatus for 72 hours	1.1 – 2.4 μ M/mL	Not determined	Decrease cellular proliferation	[26]
HeLa	Roots	Methanol, Water, Petroleum Ether, n-Butanol, Acetone, Ethyl Acetate	20 μ M	Apoptosis regulation and reactive oxygen species induction	Decrease cellular proliferation	[87]
Esophageal Cancer						

Cancer Type	Part Used	Extraction Method	IC ₅₀	Proposed Mechanisms	Results Description	References
Eca109	Roots	Ethanol by maceration, Petroleum Ether by liquid-liquid extraction	10.55 – 43.75 μ M	Migration Inhibition, Prefoliation Prevention, Apoptosis Induction; Inhibition of the cell migration and expression of MMP-2 and MPP-9, modulation of the autophagy process, Induction of ROS	Decrease cellular proliferation and inhibit cell migration	[27]
		Hydro-distillation using a Clevenger-type device	6.97 – 24.29 μ g/mL	Migration Inhibition, Prefoliation Prevention, Apoptosis Induction; Inhibition of the cell migration and expression of MMP-2 and MPP-9, modulation of the autophagy process, Induction of ROS	Decrease cellular proliferation and inhibit cell migration	[27]
KYSE150	Roots	Ethanol by maceration, Petroleum Ether by liquid-liquid extraction	8.35 – 40.78 μ M	Migration Inhibition, Prefoliation Prevention, Apoptosis Induction; Inhibition of the cell migration and expression of MMP-2 and MPP-9, modulation of the autophagy process, Induction of ROS	Decrease cellular proliferation and inhibit cell migration	[27]
Ovarian Cancer						
SK-OV-3	Roots	Methanol	1.65 – 1.83 μ M	Not determined	Decrease cellular proliferation	[46]
	Not applicable	Single isolated metabolite (dehydrocostus lactone)	10.8 μ M	Not determined	Decrease cellular proliferation	[15]
OVCAR3	Not applicable	Single isolated metabolite (dehydrocostus lactone)	13.9 μ M	Not determined	Decrease cellular proliferation	[15]
Colorectal Cancer						
SW-480	Not applicable	Two isolated metabolites (dehydrocostus lactone and costunolide)	5nM	Apoptosis regulation, caspase activity, suppression of the TNF α and NF- κ B, suppression of the Suppression of Nuclear Translocation	Decrease cellular proliferation	[16]
Oral Cancer						
KB	Roots	Methanol	30 μ g/mL	Apoptosis regulation, caspase activity	Decrease cellular proliferation	[24]
Skin Cancer						
SK-MEL-2	Roots	Methanol	0.55– 0.59 μ M	Not determined	Decrease cellular proliferation	[46]
Soft Tissue Sarcoma						
SW-872	Roots	Methanol; Petroleum Ether, Methanol by soxhlet apparatus	7.41 – 9.71 μ g/mL	Apoptosis regulation, caspase activity, gene expression activity (BCL2, P53, BAX)	Decrease cellular proliferation	[22]
SW-982	Roots	Methanol; Petroleum Ether, Methanol by soxhlet apparatus	6.17 – 9.61 μ g/mL	Apoptosis regulation, caspase activity, gene expression activity (BCL2, P53, BAX)	Decrease cellular proliferation	[22]
TE-671	Roots	Methanol; Petroleum Ether, Methanol by soxhlet apparatus	8.33 – 9.75 μ g/mL	Apoptosis regulation, caspase activity, gene expression activity (BCL2, P53, BAX)	Decrease cellular proliferation	[22]
Pancreatic Cancer						
PANC1	Roots	Hexane	0.26 – 1.2 μ M/mL	Not Determined	Decrease cellular proliferation	[26]

*Not applicable: The studies did not extract the compound, they tested the isolated compounds, which are mainly (dehydrocostus lactone or costunolide).

*Not determined: The studies did not investigate the mechanism of action of anticancer activity.

Additionally, other studies have explored alternative extraction techniques, such as nanoparticle synthesis and supercritical carbon dioxide extraction, to evaluate the antitumor potential of *S. costus* extracts [14,42,43]. One study optimized the extraction of *S. costus* oil using supercritical fluid extraction at different pressures, achieving significant inhibition with an IC₅₀ value of 0.46 μ g/mL on MCF-7 cells [42]. In contrast, magnesium oxide nanoparticles synthesized from *S. costus* methanol extracts exhibited relatively lower antiproliferative effects on MCF-7 cells, with IC₅₀ values of 80 μ g/mL and 26.7 μ g/mL for magnesium oxide and palladium nanoparticles, respectively [14,42].

Choi, (2009) tested dehydrocostuslactone on MDA-MB-231, SK-BR-3, and MDA-MB-453 cell lines, reporting IC₅₀ values ranging from 25.6 to 43.2 μ M/mL, while costunolide tested on MCF-7 cells showed an IC₅₀ value of 30.16 μ M/mL [39].

A similar pattern of inhibition, depending on plant parts, solvents, and extraction methods, was observed in other cancer types, including colon, liver, gastric, esophageal, and pancreatic cancers [14,28,29,30,37,43,44–45]. Although hexane and chloroform extracts generally showed potent inhibition, one study found no significant cytotoxicity with hexane root extracts against colon (HCT-116, HCT-29) and prostate cancer (PC-3, LNCaP, DU145), as the hexane extracts did not affect cell viability [21,38].

However, neuroblastoma cell lines (XF498, SH-AY5Y, and B103) showed susceptibility to both methanol and ethanol extracts of *S. costus*, with IC₅₀ values ranging from 15–20 μ g/mL and 0.43–1.70 μ M/mL when exposed to ethanol and methanol extracts, respectively [29,46].

Other cancer types that demonstrated sensitivity to *S. costus* extracts include ovarian, colorectal, skin, and soft tissue cancers [15,22,24].




Figure 3. Proliferation inhibition: The mechanisms of action of *S. costus* involved the modulation of the PI3K/AKT/mTOR pathway, as well as the regulation of the MAPK/ERK pathway. Additionally, *S. costus* impacts the WNT/β-Catenin pathway by reducing β-catenin levels and depicts the inhibition of the NF-κB pathway. Furthermore, the regulation of cell cycle proteins, such as CDKs and cyclins leading to induction of cell cycle arrest.

The cytotoxic potential of *S. costus* has been extensively investigated, and it has been observed that its anticancer effects are mediated through multiple mechanisms (Figure 3), including the induction of apoptosis, cell cycle arrest, modulation of the androgen receptor and autophagy processes, decreased proliferation, and alterations in cellular signaling cascades by modulating phosphorylation processes. In particular, autophagy appears to be promoted through upregulation of LC3I and LC3II levels (high LC3II/LC3I ratio) and beclin1, while mTOR phosphorylation is inhibited [32,33,47]. The interplay between autophagy and apoptosis is notable; inhibition of one can stimulate the other, suggesting a dual mechanism of action.

Ten *in vivo* studies have evaluated the anticancer activity of *S. costus*. The investigated type of cancer included breast cancer (MCF-7, MDA-MB-231), liver cancer (SMMC-7721), lung cancer (LC-540), leukemia, laryngeal carcinoma, esophageal cancer, gastric cancer (MKN-28) [47–51] (Table 3). Most studies utilized either the roots or isolated compounds (costunolide and dehydrocostus lactone), with ethanol and hexane as organic solvents for the extraction.

One study found that hexane root extract of *S. costus* inhibited hepatocellular carcinoma (HCC) with an inhibition rate of 55.71% [52]. Likewise, ethanol extracts showed anti-leukemic effects by reducing white blood cell counts to normal levels [50].

The isolated compounds also exhibit anticancer activity, the lowest dose (costunolide at 10 mg/kg/day) was tested on immunodeficient female NCr nude homozygous mice with breast and colon cancer, showing reduction of the tumor volume. The highest dose (dehydrocostus lactone at 40 mg/kg/day for 28 days) was tested also for esophageal cancer in the Eca109-b mouse model, and the results showed inhibition of the tumor growth [27]. Several studies attempt to investigate the mechanisms, the *in vivo* anticancer activity of *S. costus* is related mainly to induction of apoptosis by activating pro-apoptotic proteins such as p53 and Bax, while inhibiting anti-apoptotic proteins like Bcl-2, leading to programmed cell death, cell cycle arrest, modulating certain signaling pathways, such as EGFR, which reduces the proliferation and invasion of cancer cells, and suppress PI3K/Akt and MEK/P38 pathways, reduction the inflammatory process by suppression the level of TNF-α and NF-κB, and induction of reactive oxygen species.

Table 3. Comprehensive analysis of *S. costus* reported *in vivo* studies: treatment protocols and observed effects.

Cancer Type	Animal Model	Part Used	Extraction Method	Dose	Proposed Mechanisms	Results Description	References
Breast Cancer							
MCF-7	Adult Sprague Dawley (SD) rats (sex-female; weight-160 ±20 g; age-6-8 weeks)	Roots	Ethanol by sonication	(100, 250 and 500 mg/kg BW)	Not determined	Inhibits the pulmonary metastases breast cancer	[51]
	Six-week-old nude (Nu/Nu) mice	Not applicable	Single isolated metabolite (costunolide)	20 µM Three times a week for 30 days	Suppress breast cancer growth and metastases by inhibiting TNFα-induced NF-κB activation	Inhibits tumor growth and prevent migration	[47]
MDA-MB-23	Female BALB/c nude mice (4 weeks old)	Roots	Hexane by sonication	20 mg/kg/day	Cell cycle arrest and apoptosis regulations	Inhibits tumor growth	[88]
Liver Cancer							
Not determined	Albino Swiss mice (aged 8-10 weeks, with an average body weight of 28±1.5 g)	Roots	Ethanol	400, 600, 800mg/Kg	Cell cycle arrest and apoptosis regulations	Inhibits tumor growth	[48]
SMMC-7721	Male nude mice (4 weeks old; BALB/c-nude)	Roots	Hexane	15 mg/kg/day	Apoptosis and anti-metastatic activity.	Inhibits tumor growth	[52]
Lung Cancer							
LC-540	Adult Sprague Dawley (SD) rats (sex-female; weight-160 ±20 g; age-6-8 weeks)	Roots	Ethanol	100, 250 and 500 mg/kg BW	Not determined	Inhibits tumor growth	[89]
Leukemia							
Not determined	Adult male albino rats (180-220g); Male nude mice (4 weeks old; BALB/c-nude)	Roots	Ethanol	(300mg/Kg/day) orally for 4 weeks	Not determined	Inhibits tumor growth	[50]
Laryngeal Cancer							
Not determined	Female nude mice (BALB/c nu/nu, 4-5 weeks old, 18-19 g)	Roots	Ethanol by maceration	10, 15 mg/kg	Inhibition of PI3K/Akt/Bad pathway	Inhibits tumor growth	[90]
Esophageal Cancer							
Not determined	SPF-grade female BALB/c nude mice aged 4-5 weeks	Roots	Ethanol by maceration, Petroleum Ether by liquid-liquid extraction	(0, 20, and 40 mg/kg/day) for 28 days	Migration Inhibition, Prefoliation Prevention, Apoptosis Induction; Inhibition of the cell migration and expression of MMP-2 and MPP-9, modulation of the autophagy process, Induction of ROS	Inhibits tumor growth and migration	[27]
Gastric Cancer							
MKN-28	Female BALB/c nude mice each weighing 20 g ± 2 g	Not applicable	Single isolated metabolite (dehydrocostus lactone)	15, 30 mg/kg/day	Inhibition of autophagy	Inhibits tumor growth	[49]

*Not applicable: The studies did not extract the compound, they tested the isolated compounds, which are mainly (dehydrocostus lactone or costunolide).

*Not determined: The studies did not determine the type of cell line, or did not investigate the mechanism of action of anticancer activity.

3.2. *Lepidium sativum*

Fourteen studies have investigated the anticancer activity of *L. sativum* on various cancer types, such as liver (HuH-7 and HEPG-2), breast cancer (MCF-7), colon cancer (DLD-1, HCT-116, HT-15, HT-29, SW480, HTB-38, and Caco2), cervical cancer (HeLa 2), lung cancer (A-549 cell line), prostate cancer cells (P-C3), endometrium cancer (ECC-1), tongue squamous carcinoma (CAL-27), melanoma cancer (A-375 cell line), neuroblastoma (IMR-32), ovarian cancer (OV17R), leukemia (Jurkat E6-1)[53-66]. The studies utilized various plant parts, including leaves, roots and seeds, with the most employed seeds being the most commonly used part.

Liver cancer was the most commonly studied cancer type. Studies reported similar IC₅₀ values

across different cell lines, plant parts, and extraction solvents [58,64], particularly when polar solvents were used. This pattern was also observed in other cancer types, including breast, colon, cervical, lung, prostate, endometrial, tongue squamous cell carcinoma, and leukemia [54,55,57,60,66]. However, the results showed variability in cytotoxic activity.

In a study by Abd-elmegeed et al. (2023), phenolic compounds, such as rutin, benzoic acid, cinnamic acid, and vanillin were isolated and evaluated, revealing IC₅₀ values ranging from 28.8 µg/mL to 64.32 µg/mL [53]. Furthermore, Ibrahim et al. (2023) demonstrated that *L. sativum* ethanol extracts that are treated with glucosinolates showed inhibition of cancer cells, prostate cancer (PC-3), colon cancer (Caco2), lung cancer (A-549), and liver cancer

(HepG2) with IC_{50} ranges 38.5-92.6 mg/mL, without effect normal cell lines [59].

Nanoparticles synthesis using *L. sativum* extracts has also been explored. Meer et al. (2022), and Efati et al. (2023) reported enhanced cytotoxic potential of *L. sativum* extracts against colorectal adenocarcinoma (SW480) and colon adenocarcinoma (HT-29 and Caco-2) at different degrees of temperature, the lowest IC_{50} (13.14 μ g/mL) was detected to SW480 with ZnO at 350 °C [57,63]. In contrast, Amina et al., (2021) study of Ag-MgO nanoparticles found no enhancement of *L. sativum* extracts [55].

Several studies have investigated the mechanism of action underlying the anticancer effects of *L. sativum*. These studies demonstrated that the anticancer activity is related mainly to induction of apoptosis and cell cycle arrest. *L. sativum* extracts showed upregulation of pro-apoptotic proteins such as BAX, p53, and caspases 3/7, alongside the downregulation of anti-apoptotic proteins like Bcl-2 (Figure 4) [57]. Additionally, upregulation of SMAD2 and SMAD3 expression has been observed in the live cancer cell upon exposure to *L. sativum* extracts. Moreover, *L. sativum* extracts showed induction of cell cycle arrest at the S phase, thereby inhibiting their proliferation (Table 4) [59].

3.3. *Rhus tripartite*

The cytotoxic potential of *R. tripartite* leaves and roots was examined in four studies, using diverse cancer cell lines, including acute myeloid leukemia (THP-1), myelogenous leukemia (K-562), colon cancer (DLD-1, Caco-2), breast cancer (MCF-7), lung cancer (A-549) (Table 6) [67–71]. The extraction process used butanol, methanol, ethanol, and ethyl acetate as organic solvents. The lowest IC_{50} value (39.83 μ g/mL) was reported for methanol extracts against colon adenocarcinoma DLD-1 cell line [68].

In contrast, aqueous extracts showed lower cytotoxic activity with IC_{50} values 195.37 μ g/mL and 200 μ g/mL against A-549 and DLD-1) cell lines, respectively. Similarly, in Tlili et al. (2019) reported IC_{50} values less than 50 μ g/mL for methanol extracts against CaCo-2 and K-562 cell lines [71].

The mechanism of action for *R. tripartite* extractions is thoroughly explained by Tlili et al., 2021, which involves the inhibition of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT mammalian target of rapamycin (mTOR) pathway that eventually results in the induction of apoptosis and the suppression of tumor growth, as shown previously in Figure 4 [70].




Figure 4. Apoptosis and autophagy: *S. costus* and *L. sativum* activate p53, which leads to DNA damage response, cell cycle arrest, and apoptosis by upregulating pro-apoptotic proteins like Bax and Bak while down regulating anti-apoptotic proteins such as Bcl-2 and Mcl-1. Additionally, *S. costus* influences autophagy pathways, including Beclin-1 and the interaction of death receptors, leading to autophagic cell death. It includes also the apoptosis by ROS generation, which leads to mitochondrial dysfunction and apoptosis. *R. tripartite* is also involved in the modulation of the PI3K/AKT/mTOR pathway.

Table 4. Comprehensive analysis of *in vitro* anticancer studies on *L. sativum*: cell lines, extracts, and mechanisms of action.

Cancer Type	Plant Part	Extraction Method	IC ₅₀	Proposed Mechanism	Results Description	Reference
Liver Cancer						
HepG-2	Seeds	Methylene chloride, n-Hexane, Ethyl Acetate, Butanol, Methanol	45 – 63.8 µg/mL	Apoptosis and downregulation of EGFR	Decrease cellular proliferation	[64]
		Aqueous with ZnO nanoparticles	100 µg/mL	Induction of ROS	Decrease cellular proliferation	[63]
	Seeds and leaf	Ethanol and Aqueous	382.2 mg /mL	Not determined	Decrease cellular proliferation	[58]
	Leaves and roots	Ethanol extracts with glucosinolate	38.5 – 81.2 µg/mL	Apoptotic regulation, caspase activity, cell cycle effects	Decrease cellular proliferation, the glucosinolate extracts enhance the selectivity, it did not affect normal cell lines	[59]
HuH-7	Seeds	Methylene chloride, n-Hexane, Ethyl Acetate, Butanol, Methanol;	59 – 63.5 µg/mL	Gene expression modulation (EGFR, BCL2, SMAD3, BAX, P53)	Decrease cellular proliferation	[64]
Breast Cancer						
MCF-7	Seeds	Aqueous	70% concentration of <i>L. sativum</i> inhibited the growth by 64.03%	Not determined	Decrease cellular proliferation	[62]
		Crude and soxhlet Methanol	88.49 - 136.75 µg/mL	Not determined	Decrease cellular proliferation	[65]
	Leaves and Roots	Ethanol extracts with glucosinolates	61 - 71.1 µg/mL	Apoptosis regulation, caspase activity, cell cycle effects	Decrease cellular proliferation, the glucosinolate extracts enhance the selectivity, it did not affect normal cell lines	[59]
Colon Cancer						
CaCo-2	Seeds	Aqueous extract with ZnO-NPs	18.45 - 105.9 µg/mL	Gene expression modulation (p53, Bax, Bcl-2)	Decrease cellular proliferation	[57]
	Leaves	Ethanol extracts with glucosinolates	56.6 - 89.9 µg/mL	Apoptotic regulation, caspase activity, cell cycle effects	Decrease cellular proliferation, the glucosinolate extracts enhance the selectivity, it did not affect normal cell lines	[59]
DLD-1	Above-Ground Parts	Methanol by maceration	100 µg/mL (DLD-1)	100 µg/mL	Decrease cellular proliferation	[66]
HT-29	Seeds	n-Hexane, Chloroform, Ethyl Acetate Methanol by soxhlet apparatus	100 µg/mL	Not determined	Decrease cellular proliferation	[60]
HT-15	Seeds	n-Hexane, Chloroform, Ethyl Acetate Methanol by soxhlet apparatus	100 µg/mL	Not determined	Decrease cellular proliferation	[60]
Cervical Cancer						
HeLA - 2	Seeds	Soxhlet extraction with silver nanoparticles	135 - 220.35 µg/mL	ROS generation	Decrease cellular proliferation, and nanoparticles formulation enhances the anticancer activity	[55]
	Leaves	Ethanol maceration extracts	100 µg/mL (at second day)	Apoptosis induction	Decrease cellular proliferation	[61]
Lung Cancer						
A-549	Seeds	n-Hexane, Chloroform, Ethyl Acetate Methanol by soxhlet apparatus	100 µg/mL	Not determined	Decrease cellular proliferation	[60]
	Leaves and Roots	Ethanol extracts with glucosinolates	42.3 - 92.6 µg/mL	Apoptotic regulation, caspase activity, cell cycle effects	Decrease cellular proliferation, the glucosinolate extracts enhance the selectivity, it did not affect normal cell lines	[59]
Prostate Cancer						
PC-3	Seeds and leaf Calli	Aqueous and Ethanol extracts	113.6 mg/mL	Not determined	Decrease cellular proliferation	[58]
	Leaves and Roots	Ethanol extracts with glucosinolates	51.4 - 72.4 µg/mL	Apoptotic regulation, caspase activity, cell cycle effects	Decrease cellular proliferation, the glucosinolate extracts enhance the selectivity, it did not affect normal cell lines	[59]
Endometrium Cancer						
ECC-1	Above-Ground Parts	Methanol extracts by maceration	353 µg/mL	Not determined	Decrease cellular proliferation	[66]
Tongue Squamous Carcinoma						
CAL-27	Leaves	Aqueous extract	100 µg/mL	ROS generation induction	Decrease cellular proliferation	[54]
Melanoma						
A-375	Leaves and roots	Ethanol extracts with glucosinolates	Not determined	Apoptotic regulation, caspase activity, cell cycle	Decrease cellular proliferation, the glucosinolate extracts	[59]

Cancer Type	Plant Part	Extraction Method	IC ₅₀	Proposed Mechanism	Results Description	Reference
				effects	enhance the selectivity, it did not affect normal cell lines	
Neuroblastoma						
IMR-32	Seeds	Various solvents by soxhlet apparatus	100 µg/mL	Not determined	Decrease cellular proliferation	[60]
Ovarian Adenocarcinoma						
OV17R	Seeds	Various extracts and HPLC	28.8 - 64.32 µg/mL	Not determined	Decrease cellular proliferation	[53]
Leukemia						
Jurkat E6-1	Seeds	Tertiary Alkaloid extract	75.25 mg/mL	Apoptosis via DNA laddering, caspase-3 activity	Decrease cellular proliferation	[56]
Colorectal Cancer						
SW-480	Seeds	Aqueous extract\ green synthesis of ZnO-NP	13.14 - 100 µg/mL	Gene expression modulation (EGFR, BCL2, SMAD3, BAX, P53)	Decrease cellular proliferation	[57]

*Not determined: The studies did not investigate the mechanism of action of anticancer activity.

Table 5. Comprehensive analysis of *L. sativum* reported in *in vivo* studies: treatment protocols and observed effects.

Cancer Type	Animal Model	Part Used	Extraction Method	Dose	Proposed Mechanisms	Results Description	References
Ehrlich ascites carcinoma (EAC)							
Ehrlich ascites carcinoma (EAC)	Female Swiss albino mice	Seeds	Dichloromethane and Ethyl Acetate.	500 mg/kg	Decreased chromosomal aberration and DNA fragmentation induced by EAC in mice	The mice have an increased lifespan by 37.14%.	[82]

Table 6. Comprehensive analysis of *in vitro* anticancer studies on *R. tripartite*: cell lines, extracts, and mechanisms of action.

Cancer Type	Part Used	Extraction Method	IC ₅₀	Proposed Mechanisms	Results Description	References
Acute Myeloid Leukemia						
THP-1	Leaves	Acetone, Methanol buy maceration	63 µg/mL	Apoptosis induction by inhibiting PI3K/AKT/mTOR signaling pathway.	Decrease cellular proliferation	[70]
K-562	Aerial Parts	Acetone, Methanol buy maceration	42.89 µg/mL	Not determined	Decrease cellular proliferation	[71]
Colon Adenocarcinoma						
DLD-1	Roots	Hexane, Dichloromethane, Methanol, Water by soxhlet extraction	39.83 - 200 µg/mL	Not determined	Decrease cellular proliferation	[68]
CaCo-2	Aerial parts	Acetone, Methanol buy maceration	44.87 µg/mL	Not determined	Decrease cellular proliferation	[71]
Breast Adenocarcinoma						
MCF-7	Roots	Ethanol by maceration, then sequential partitioning: Hexane, Ethyl acetate, n-butanol	100 µg/mL	Not determined	Decrease cellular proliferation	[69]
Lung Cancer						
A-549	Roots	Hexane, Dichloromethane, Methanol, Water by soxhlet extraction	60.69 - 205.52 µg/mL	Not determined	Decrease cellular proliferation	[68]

*Not determined: The studies did not investigate the mechanism of action of anticancer activity.

3.4. *Pyrus communis*

Cytotoxic potential of *P. communis* has been examined in two studies on various cancer types, including lung cancer (A549, WI-38), prostate cancer (LNCaP), urinary bladder cancer (HCV29T), kidney cancer (A-498), mouse myelogenous leukemia carcinoma (M-NFS-60), ovary cancer (CHO-K1) [72,73].

Both studies utilized the fruits of *P. communis*. The study that utilized hydroinstillation extraction method showed higher cytotoxicity, with IC₅₀ values ranging values: from 30.9 to 105 µg/mL. In contrast,

the study employing the UPLC-PDA-MS extraction method showed lower cytotoxicity, with IC₅₀ values ranging from: 0.5 - to 3.2 mg/mL (Table 7) [72,73].

3.5. *Chenopodium murale*

Only one *in vitro* study has evaluated *C. murale*'s anticancer activity in breast cancer (MCF-7) and liver cancer (HCAM), with leaves extracted using an ethanol solvent. The investigation found that the extraction had weak cytotoxic activity, with IC₅₀ of 1504 µg/mL for breast cancer and 1267 µg/mL for liver cancer cells (Table 8) [74].

3.6. *Erucaria hispanica*

E. hispanica was investigated in one study involving four different cancer cell lines, breast (MCF7), liver (HEPG2), cervix (HELA) and colon (HCT116) cancers, utilizing methanol extracts of aerial parts of *E. hispanica* [10]. The results showed IC₅₀ values 18 µg/mL, 20.8 µg/mL, 14.7 µg/mL and 21.4 µg/mL respectively (Table 9).

3.7. *Trigonella hamosa*

A single study has investigated to explore the anticancer activity of methanol extracts from *T. hamosa* aerial parts. The reported IC₅₀ values were 6.71 µg/mL for breast cancer (MDA-MB-231), 4.93 µg/mL for lung cancer (A549), and 13.74 µg/mL for colon cancer (HTC-166) (Table 10) [75].

Table 7. Comprehensive analysis of *in vitro* anticancer studies on *P. communis*: cell lines, extracts, and mechanisms of action.

Cancer Type	Part Used	Extraction Method	IC ₅₀	Proposed Mechanism	Results Description	References
Lung Cancer						
A-549	Fruits	Hydroinstillation	30.9 µg/mL	Not determined	Decrease cellular proliferation	[72]
	Fruits	UPLC-PDA-MS	0.5 - 2.5 mg/mL	Not determined	Decrease cellular proliferation	[73]
WI-38	Fruits	Hydroinstillation	55.9 µg/ml	Not determined	Decrease cellular proliferation	[72]
Colon Cancer						
HT-29	Fruits	UPLC-PDA-MS	0.5 - 2.5 mg/mL	Not determined	Decrease cellular proliferation	[73]
Breast Cancer						
MCF-7	Fruits	UPLC-PDA-MS	0.4 - 2.4 mg/mL	Not determined	Decrease cellular proliferation	[73]
Prostate Cancer						
LNCAp	Fruits	UPLC-PDA-MS	0.5 - 1.4 mg/mL	Not determined	Decrease cellular proliferation	[73]
Urinary Cancer						
HCV29T	Fruits	UPLC-PDA-MS	0.5 - 1.5 mg/mL	Not determined	Decrease cellular proliferation	[73]
Kidney Cancer						
A498	Fruits	UPLC-PDA-MS	1.8 - 3.2 mg/mL	Not determined	Decrease cellular proliferation	[73]
Ovary Cancer						
CHO-K1	Fruits	Hydroinstillation	105 µg/mL	Not determined	Decrease cellular proliferation	[72]
Leukemia						
M-NFS-60	Fruits	Hydroinstillation	56.5 µg/mL	Not determined	Decrease cellular proliferation	[72]

*Not determined: The study did not investigate the mechanism of action of anticancer activity.

Table 8. Comprehensive analysis of *in vitro* anticancer studies on *C. murale*: cell lines, extracts, and mechanisms of action.

Cancer Type	Part used	Extraction Method	IC ₅₀	Proposed Mechanisms	Results Description	References
Breast Cancer						
MCF-7	Leaves	Ethanol extracts microwave assisted extraction.	1504 µg/mL	Not determined	Decrease cellular proliferation	[74]
Liver Cancer						
HCAM	Leaves	Ethanol extracts microwave assisted extraction.	1267 µg/mL	Not determined	Decrease cellular proliferation	[74]

*Not determined: The studies did not investigate the mechanism of action anticancer activity.

Table 9. Comprehensive analysis of *in vitro* anticancer studies on *E. hispanica*: cell lines, extracts, and mechanisms of action.

Cancer Type	Part Used	Extraction and Method	IC ₅₀	Proposed Mechanism	Results Description	References
Breast Cancer						
MCF-7	Ground, Aerial parts	Methanol	18 µg/mL	Not determined	Decrease cellular proliferation	[10]
Liver Cancer						
HePG-2	Ground, Aerial parts	Methanol	20.8 µg/mL	Not determined	Decrease cellular proliferation	[10]
Cervical Cancer						
HeLA-2	Ground, Aerial parts	Methanol	14.7 µg/mL	Not determined	Decrease cellular proliferation	[10]
Colon Cancer						
HCT-116	Ground, Aerial parts	Methanol	21.4 µg/mL	Not determined	Decrease cellular proliferation	[10]

* Not determined: The studies did not investigate the mechanism of action of anticancer activity.

Table 10. Comprehensive analysis of *in vitro* anticancer studies on *T. hamosa*: cell lines, extracts, and mechanisms of action.

Cancer Type	Part Used	Extraction and Method	IC ₅₀	Proposed Mechanism	Results Description	References
Breast Cancer						
MDA-MB-231	Aerial Parts	Methanol	28.9 µM	Not determined	Decrease cellular proliferation	[75]
Lung Cancer						
A-549	Aerial Parts	Methanol	21.2 µM	Not determined	Decrease cellular proliferation	[75]
Colon Cancer						
HCT-116	Aerial Parts	Methanol	59.1 µM	Not determined	Decrease cellular proliferation	[75]

*Not determined: The studies did not investigate the mechanism of action of anticancer activity.

4. Discussion

Medicinal plants have long served as a valuable source for the discovery of novel therapeutic agents, particularly in the treatment of diseases such as cancer [76]. Cancer remains a complex and life-threatening condition, contributing to rising mortality rates globally. Additionally, the development of resistance to existing treatments further complicates cancer management and presents significant challenges [77]. Consequently, there is a pressing need to identify new therapeutic agents that can enhance current treatment strategies and address resistance issues. Several medicinal plants have shown promising therapeutic properties, including anticancer activity.

This systematic review critically assessed the available evidence on the anticancer potential of selected medicinal plants. A total of sixty-nine studies were identified that investigated the anticancer effects of for *S. costus*, *L. sativum*, *Rhus tripartite*, *C. murale*, *P. communis*, *E. hispanica*, *T. hamosa*. In contrast, *A. ochroleuca*, and *G. odoratum* have not yet been evaluated for their anticancer potential.

Among these, *S. costus* was the most extensively studied. It has been tested against various cancer types, most notably breast (MCF-7, MDA-MB-231, SK-BR-3), liver (HepG2), and colon cancers (HCT-116, HT-29). The cytotoxic activity of *S. costus* varied depending on the extract type and cell line. For instance, non-polar organic solvents like hexane and chloroform demonstrated high potency, with IC_{50} 0.4 μ g/mL – 2.1 μ g/mL [30]. However, this potency did not consistently extend to all cancers – prostate cancer cell lines (PC-3, LNCaP, DU145), for example, showed resistance to hexane extracts [21,38]. In comparison, extracts prepared with polar solvents (methanol, ethanol, butanol) generally showed lower potency (IC_{50} values: 10 μ g/mL to > 100 μ g/mL), suggesting solvent polarity significantly influences the bioactivity of phytoconstituents present in *S. costus* [37,45,78]. In contrast, other cancer types showed to be sensitive, such as ovarian, colorectal, skin, and soft tissue, regardless of polarity of the solvents or extraction method.

Skin cancer (SK-MEL-2) cells showed exceptional sensitivity to costunolide and dehydrocostus lacton, two well-characterized sesquiterpene lactones isolated from *S. costus*, with IC_{50} ranging from 4.7 μ M to 60 μ M. These compounds demonstrated consistent tumor-suppressive activity across various studies. Advanced extraction techniques like supercritical CO₂ extraction yielded highly potent results, with IC_{50} values of 0.44–0.74 μ g/mL against HCT-116, MCF-7, and HepG2 cells [42]. Nanoparticle formulations also enhanced

cytotoxicity: methanolic *S. costus*-derived palladium nanoparticles showed IC_{50} values of 7.8–26.7 μ g/mL, whereas magnesium oxide nanoparticles were moderately effective (IC_{50} = 80 μ g/mL) [14,43]. These findings highlight that supercritical extraction and specific nanoparticle formulations can optimize *S. costus*'s therapeutic potential.

In vivo studies support the anticancer potential of *S. costus*: hexane extracts demonstrated a 55.71% inhibition rate on hepatocellular carcinoma (HCC) [52]. While ethanol extracts effectively normalized white blood cell counts in leukemia [50]. Costunolide (10 mg/kg/day) reduced breast and colon tumor volumes in mice, while dehydrocostuslactone (40 mg/kg/day) inhibited esophageal tumor growth [78]. These findings reinforce the therapeutic relevance of *S. costus*.

Mechanistically, *S. costus* exhibits multiple modes of action, including inhibition of the Epidermal Growth Factor Receptor (EGFR) and PI3K/Akt signaling pathways, as well as suppression of inflammation, invasion, and metastasis. EGFR dysregulation is linked to tumor progression. Thereover, targeting EGFR suppresses cancer cell proliferation [79]. Additionally, *S. costus* downregulates TNF- α and NF- κ B, key mediators of tumor metastasis and chronic inflammation [80]. The ability to modulate multiple pathways makes *S. costus* a promising multi-targeted anticancer agent.

L. sativum has been evaluated in fourteen studies on different cancers, highlighting its potential versatility. The anticancer potency varied depending on extraction solvent and methodology. For instance, Nazir et al., (2021) observed differential activity across A-549 and HepG2 cell lines using various organic solvents [64]. Furthermore, the selectivity inhibition of the cancer cells has been tested in a study by Ibrahim et al. (2023), who utilized glucosinolates with *L. sativum* ethanol extracts [59]. The IC_{50} values for these glucosinolate-treated extracts ranged from 38.5 to 92.6 μ g/mL and were noted to have no adverse effects on normal cell lines. While some nanoparticle-based formulations improved bioactivity [57], others, like Ag-MgO nanoparticles, showed no enhancement [55], suggesting that nanoparticle composition critically influences therapeutic efficacy.

Although most *L. sativum* studies were *in vitro*, one *in vivo* study demonstrated a 37.14% increase in lifespan in mice with Ehrlich ascites carcinoma treated with *L. sativum* seed extracts [81]. *L. sativum* extracts induced apoptosis and cell cycle arrest – key processes in cancer treatment [59]. Apoptosis, a programmed cell death, is regulated at the genetic level, ensuring the orderly and efficient removal of damaged cells [82]. Thus, the ability of *L. sativum*

extracts to induce the apoptosis underlying its potential as a therapeutic agent.

R. tripartite has demonstrated cytotoxic effects. Methanol extracts exhibited the lowest IC₅₀ values, particularly against the DLD-1 colon adenocarcinoma cell line (39.83 µg/mL) [68]. Aqueous extracts, on the other hand, showed less cytotoxicity, reaffirming the importance of solvent selection. The primary mechanism identified involves inhibition of the PI3K/AKT/mTOR pathway [70]. The PI3K/AKT/mTOR pathway plays a crucial role in survival, growth, and proliferation of the cells. Inhibition of this pathway results in suppression of the tumor progression [83].

The cytotoxic potential of *P. communis* was moderate and varied between studies, even though both used fruit extracts. IC₅₀ values ranged from 30.9 to 105 µg/mL in one study [72]; While the other reported lower cytotoxicity (IC₅₀: 0.4–3.2 mg/mL), possibly due to differences in extraction methods (hydrodistillation vs. UPLC-PDA-MS) [73]. While the findings indicate promising activity, the limited number of studies necessitates further investigation to validate their efficacy against cancer.

In contrast, *C. murale* demonstrated weak anticancer activity, with IC₅₀ values of 1504 µg/mL (MCF-7) and 1267 µg/mL (liver cancer) [74]. These values indicate a relatively weak cytotoxic potential, which may limit its applicability in cancer therapy. However, further research using different extraction approaches or targeting other cancer types may yield better results.

E. hispanica showed moderate cytotoxic activity in one study, with IC₅₀ values ranging from 14.7 µg/mL to 21.4 µg/mL across different cancer cell lines [10]. Similarly, *T. hamosa* demonstrated promising cytotoxicity (IC₅₀ = 6.7–13.7 µg/mL), though only one study has investigated its potential [75]. The limited data highlights the necessity for further investigation into these plants to better understand their anticancer potential, considering the influence of plant parts, different solvents and mechanism of action.

This systematic review has several important limitations. First, the literature search was conducted exclusively using Google Scholar, which may not provide the same level of indexing rigor or coverage as more specialized scientific databases. This may have led to the omission of relevant studies. Second, the review only included studies published in English, introducing potential language bias. Another major limitation is the lack of formal risk of bias assessment of the included studies, which undermines the ability to critically evaluate the quality and reliability of the evidence. Furthermore,

there was considerable heterogeneity in study designs, plant parts used, extraction methods, solvents, cancer types, and assay conditions, which makes it difficult to compare findings or draw definitive conclusions. Lastly, while some *in vivo* studies were included, the review is heavily weighted toward *in vitro* data, limiting the applicability of findings to clinical or physiological settings.

5. Conclusion

Cancer remains a complex, multifactorial disease that is difficult to treat. For decades, using plants as a source of potential therapeutic agents has been a key approach. This systematic review highlights promising anticancer properties of several plant extracts, particularly *S. costus*, *L. sativum*, and *R. tripartite*, due to their ability to induce apoptosis. Extensive *in vitro* and *in vivo* studies on *S. costus* have demonstrated its significant cytotoxic potential. For *S. costus* *in vitro* studies, the polarity of the extraction solvents played a significant role in cytotoxic potency. *L. sativum* and *R. tripartita* also demonstrated notable activity, other plants—such as *P. communis*, *C. murale*, *E. hispanica*, and *T. hamosa*—require further exploration. Importantly, *A. ochroleuca* and *G. odoratum* have not been studied at all in this context and represent important gaps in literature.

Overall, this review underscores the therapeutic promise of several medicinal plants in cancer treatment and emphasizes the need for standardized methodologies, *in vivo* studies, and deeper mechanistic investigations to fully harness their potential.

Abbreviations

ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; DHE: dehydrocostuslactone; EGF: epidermal growth factor; ER: endoplasmic reticulum; GL: glucosinolates of leaf cell suspension; GLM: glucosinolates of leaf cell suspension treated with L-methionine; GLT: glucosinolates of leaf cell suspension treated with L-tyrosine; GSH: glutathione; LAMP: lysosome-associated membrane protein; LC3II: microtubule-associated protein 1 light chain 3-II lipidation chain indicator; MDA: malondialdehyde; MEK: mitogen-activated protein kinase kinase MAPKK; MMP: matrix metalloproteinase; MS: mass spectrometry; NF-κB: nuclear factor-kappa B; OL: petroleum ether extract of leaf cell suspension; OR: petroleum ether extract of root cell suspension; PARP: poly ADP-ribose polymerase; PDA: photodiode array detector; PI3K/AKT/mTOR: phosphatidylinositol 3-kinase PI3K protein kinase B AKT mammalian

target of rapamycin mTOR; RNS: reactive nitrogen species; ROS: reactive oxygen species; TIMP: tissue inhibitor of metalloproteinases; TNF- α : tumor necrosis factor-alpha; UPLC: ultra-performance liquid chromatography; VEGF: vascular endothelial growth factor.

Acknowledgements

The authors want to express their sincerest gratitude to King Abdullah International Medical Research Center (KAIMRC) for supporting this research project (grant number #SPR24/007/5).

Funding

This research project (grant number #SPR24/007/5) was financially supported by King Abdullah International Medical Research Center (KAIMRC).

Competing Interests

The authors have declared that no competing interest exists.

References

- Majolo F, de Oliveira Becker Delwing LK, Marmitt DJ, Bustamante-Filho IC, Goettert MI. Medicinal plants and bioactive natural compounds for cancer treatment: Important advances for drug discovery. *Phytochem. Lett.* 2019;31:196–207.
- Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. *J. Ethnopharmacol.* 2005;100:72–9.
- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* 2024;74:229–63.
- Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. *Adv. Pharm. Bull.* 2017;7:339–48.
- Abdel-Aziz MS, Shaheen MS, El-Nekeety AA, Abdel-Wahhab MA. Antioxidant and antibacterial activity of silver nanoparticles biosynthesized using *Chenopodium murale* leaf extract. *SI Nanomater. Energy Environ. Appl.* 2014;18:356–63.
- Abdelwahab SI, Taha MME, Alhazmi HA, Ahsan W, Rehman ZU, Bratty MA, et al. Phytochemical profiling of *Costus* (*Saussurea lappa* Clarke) root essential oil, and its antimicrobial and toxicological effects. *Trop. J. Pharm. Res.* 2021;18:2155–60.
- Ahmed SS, Ibrahim ME, El-Sawi SA, Motawe HM. Monitoring and evaluation of some Egyptian wild plants grown in the Eastern Desert of Egypt. *J Mater Env. Sci* 2018;9:1692–9.
- Chatoui K, Talbaoui A, Aneb M, Bakri Y, Harhar H, Tabyaoui M. Phytochemical screening, antioxidant and antibacterial activity of *Lepidium sativum* seeds from Morocco. *J Mater Env.* 2016;7.
- Ledoux A, Martin B, De Tullio P, Tits M, Wauters JN, Choi YH, et al. Metabolomics analysis of *Galium odoratum* (L.) Scop.: impact of the plant population origin and growth conditions. 2015.
- Marzouk MM. Flavonoid constituents and cytotoxic activity of *Erucaria hispanica* (L.) Druce growing wild in Egypt. *Arab. J. Chem.* 2016;9:S411–5.
- Rao H, Ahmad S, Y.Aati H, Basit A, Ahmad I, Ahmad Ghalloo B, et al. Phytochemical screening, biological evaluation, and molecular docking studies of aerial parts of *Trigonella hamosa* (branched Fenugreek). *Arab. J. Chem.* 2023;16:104795.
- Sánchez-Mendoza ME, Castillo-Henkel C, Navarrete A. Relaxant action mechanism of berberine identified as the active principle of *Argemone ochroleuca* Sweet in guinea-pig tracheal smooth muscle. *J. Pharm. Pharmacol.* 2008;60:229–36.
- Sharma K, Pasricha V, Satpathy G, Gupta R K. Evaluation of phytochemical and antioxidant activity of raw *Pyrus communis* (l), an underexploited fruit. *J. Pharmacogn. Phytochem.* 2015;3:46–50.
- Al-Radadi NS. *Saussurea costus* for sustainable and eco-friendly synthesis of palladium nanoparticles and their biological activities. *Arab. J. Chem.* 2022;15:104294.
- Choi. Evaluation of anticancer activity of dehydrocostuslactone in vitro. *Mol. Med. Rep.* [Internet] 2009 [cited 2024 Nov 16];3. Available from: <http://www.spandidos-publications.com/mmr/3/1/185>
- Dong G zhi, Shim AR, Hyeon JS, Lee HJ, Ryu JH. Inhibition of Wnt/ β -Catenin Pathway by Dehydrocostus Lactone and Costunolide in Colon Cancer Cells: SAUSSUREA LAPPA INHIBITS WNT/ β -CATENIN PATHWAY. *Phytother. Res.* 2015;29:680–6.
- Gao K, Chen Z, Zhang N, Jiang P. High throughput virtual screening and validation of Plant-Based EGFR L858R kinase inhibitors against Non-Small cell lung Cancer: An integrated approach Utilizing GC-MS, network Pharmacology, Docking, and molecular dynamics. *Saudi Pharm. J.* 2024;32:102139.
- Hsu YL, Wu LY, Kuo PL. Dehydrocostuslactone, a Medicinal Plant-Derived Sesquiterpene Lactone, Induces Apoptosis Coupled to Endoplasmic Reticulum Stress in Liver Cancer Cells. *J. Pharmacol. Exp. Ther.* 2009;329:808–19.
- Hu XF, Liu WX, Zhang R, Zhang W, Wang C, Chen M, et al. Essential oil from *Saussurea costus* inhibits proliferation and migration of Eca109 cells via mitochondrial apoptosis and STAT3 signaling. *Asian Pac. J. Trop. Biomed.* 2022;12:253–61.
- Hua P, Zhang G, Zhang Y, Sun M, Cui R, Li X, et al. Costunolide induces G1/S phase arrest and activates mitochondrial-mediated apoptotic pathways in SK-MES 1 human lung squamous carcinoma cells. *Oncol. Lett.* 2016;11:2780–6.
- Kim EJ, Lim SS, Park SY, Shin HK, Kim JS, Park JHY. Apoptosis of DU145 human prostate cancer cells induced by dehydrocostus lactone isolated from the root of *Saussurea lappa*. *Food Chem. Toxicol.* 2008;46:3651–8.
- Kretschmer N, Rinner B, Stuenkel N, Kaltenecker H, Wolf E, Kunert O, et al. Effect of Costunolide and Dehydrocostus Lactone on Cell Cycle, Apoptosis, and ABC Transporter Expression in Human Soft Tissue Sarcoma Cells. *Planta Med.* 2012;78:1749–56.
- Kumar A, Kumar S, Kumar D, Agnihotri VK. UPLC/MS/MS method for quantification and cytotoxic activity of sesquiterpene lactones isolated from *Saussurea lappa*. *J. Ethnopharmacol.* 2014;155:1393–7.
- Moon SM, Yun SJ, Kook JK, Kim HJ, Choi MS, Park BR, et al. Anticancer activity of *Saussurea lappa* extract by apoptotic pathway in KB human oral cancer cells. *Pharm. Biol.* 2013;51:1372–7.
- Oh GS, Pae HO, Chung HT, Kwon JW, Lee JH, Kwon TO, et al. Dehydrocostus Lactone Enhances Tumor Necrosis Factor- α -Induced Apoptosis of Human Leukemia HL-60 Cells. *Immunopharmacol. Immunotoxicol.* 2004;26:163–75.
- Pavan Kumar Ch, Devi A, Ashok Yadav P, Rao Vadaparthi R, Shankaraiah G, Sowjanya P, et al. “Click” reaction mediated synthesis of costunolide and dehydrocostuslactone derivatives and evaluation of their cytotoxic activity. *J. Asian Nat. Prod. Res.* 2016;18:1063–78.
- Peng Y, Zhou T, Wang S, Bahetjan Y, Li X, Yang X. Dehydrocostus lactone inhibits the proliferation of esophageal cancer cells in vivo and in vitro through ROS-mediated apoptosis and autophagy. *Food Chem. Toxicol.* 2022;170:113453.
- Peng Z, Wang Y, Gu X, Wen Y, Yan C. A platform for fast screening potential anti-breast cancer compounds in traditional Chinese medicines. *Biomed. Chromatogr.* 2013;27:1759–66.
- Rahman MdA, Hong JS, Huh SO. Antiproliferative properties of *Saussurea lappa* Clarke root extract in SH-SY5Y neuroblastoma cells via intrinsic apoptotic pathway. *Anim. Cells Syst.* 2015;19:119–26.
- Shati AA, Alkhatani MA, Alfaifi MY, Elbehairi SEI, Elsaid FG, Prasanna R, et al. Secondary Metabolites of *Saussurea costus* Leaf Extract Induce Apoptosis in Breast, Liver, and Colon Cancer Cells by Caspase-3-Dependent Intrinsic Pathway. *BioMed Res. Int.* 2020;20:1–11.
- Su J, H JoKD, Jeong HG, Gyu NC, Gyu GS. Inhibition of Cellular Proliferation by p53 dependent Apoptosis and G2M Cell Cycle Arrest of *Saussurea lappa* CLARKE in AGS Gastric Cancer Cell Lines. *J. Physiol. Pathol. Korean Med.* 2004;18:1186–91.
- Tabata K, Nishimura Y, Takeda T, Kurita M, Uchiyama T, Suzuki T. Sesquiterpene lactones derived from *Saussurea lappa* induce apoptosis and inhibit invasion and migration in neuroblastoma cells. *J. Pharmacol. Sci.* 2015;127:397–403.
- Tian X, Song HS, Cho YM, Park B, Song YJ, Jang S, et al. Anticancer effect of *Saussurea lappa* extract via dual control of apoptosis and autophagy in prostate cancer cells. *Medicine (Baltimore)* 2017;96:e7606.
- Kim HR, Kim JM, Kim MS, Hwang JK, Park YJ, Yang SH, et al. *Saussurea lappa* extract suppresses TPA-induced cell invasion via inhibition of NF- κ B-dependent MMP-9 expression in MCF-7 breast cancer cells. *BMC Complement. Altern. Med.* 2014;14:170.
- Mohsen E, El-Far AH, Godugu K, Elsayed F, Mousa SA, Younis IY. SPME and solvent-based GC-MS metabolite profiling of Egyptian marketed *Saussurea costus* (Falc.) Lipsch. concerning its anticancer activity. *Phytomedicine Plus* 2022;2:100209.
- Alotaibi AA, Bepari A, Assiri RA, Niazi SK, Nayaka S, Rudrappa M, et al. *Saussurea lappa* Exhibits Anti-Oncogenic Effect in Hepatocellular Carcinoma, HepG2 Cancer Cell Line by Bcl-2 Mediated Apoptotic Pathway and Mitochondrial Cytochrome C Release. *Curr. Issues Mol. Biol.* 2021;43:1114–32.
- Bhushan A, Rani D, Tabassum M, Kumar S, Gupta PN, Gairola S, et al. HPLC-PDA Method for Quantification of Bioactive Compounds in Crude Extract and Fractions of *Aucklandia costus* Falc. and Cytotoxicity Studies against Cancer Cells. *Molecules* 2023;28:4815.

38. Kim EJ, Hong JE, Lim SS, Kwon GT, Kim J, Kim JS, et al. The Hexane Extract of *Saussurea lappa* and Its Active Principle, Dehydrocostus Lactone, Inhibit Prostate Cancer Cell Migration. *J. Med. Food* 2012;15:24-32.
39. Choi YJ, Choi YK, Ko SG, Cheon C, Kim TY. Investigation of Molecular Mechanisms Involved in Sensitivity to the Anti-Cancer Activity of Costunolide in Breast Cancer Cells. *Int. J. Mol. Sci.* 2023;24:4009.
40. Alhakamy NA, Badr-Eldin SM, Ahmed OAA, Aldawsari HM, Okbazghi SZ, Alfaleh MA, et al. Green Nanoemulsion Stabilized by In Situ Self-Assembled Natural Oil/Native Cyclodextrin Complexes: An Eco-Friendly Approach for Enhancing Anticancer Activity of Costunolide against Lung Cancer Cells. *Pharmaceutics* 2022;14:227.
41. Sun S H, Ko SG. Effects of Costunolide Derived from *Saussurea lappa* Clarke on Apoptosis in AGS Stomach Cancer Cell Lines. *J. Korean Med.* 2006;27:48-95.
42. Ahmed HY, Kareem SM, Atef A, Safwat NA, Shehata RM, Yosri M, et al. Optimization of Supercritical Carbon Dioxide Extraction of *Saussurea costus* Oil and Its Antimicrobial, Antioxidant, and Anticancer Activities. *Antioxidants* 2022;11.
43. Amina M, Al Musayeib NM, Alarfaj NA, El-Tohamy MF, Oraby HF, Al Hamoud GA, et al. Biogenic green synthesis of MgO nanoparticles using *Saussurea costus* biomasses for a comprehensive detection of their antimicrobial, cytotoxicity against MCF-7 breast cancer cells and photocatalysis potentials. *PLOS ONE* 2020;15:e0237567.
44. Kumar R, Bhardwaj P, Virmani DN, Asrani RK, Patel SK, Gupta VK, et al. Modulation of Apoptotic Signaling Pathways by *Saussurea Costus* (Falc.) Lipsch Root Ethanolic Extract on Human Breast Cancer MCF-7 Cells [Internet]. 2023 [cited 2024 Nov 16]; Available from: <https://www.ssrn.com/abstract=4513922>
45. Ko SG, Koh SH, Jun CY, Nam CG, Bae HS, Shin MK. Induction of Apoptosis by *Saussurea lappa* and *Pharbitis nil* on AGS Gastric Cancer Cells. *Biol. Pharm. Bull.* 2004;27:1604-10.
46. Jin M, Ryu JH, Ryu SY, Chung KS. Cytotoxic Effects on Human Cancer Cells and Apoptosis of a Sesquiterpene Lactone from *Saussurea lappa*. *Biomol. Ther.* 2000;8:22-6.
47. Choi YK, Cho SG, Woo SM, Yun YJ, Jo J, Kim W, et al. *Saussurea lappa* Clarke-Derived Costunolide Prevents TNF α -Induced Breast Cancer Cell Migration and Invasion by Inhibiting NF- κ B Activity. *Evid. Based Complement. Alternat. Med.* 2013;2013:1-10.
48. Al-Zayadi ZA, Shanan HK, Akool ASK. Evaluation of the Anticancer Effect of *Saussurea costus* Root Extract Against Induced Hepatic and Renal Cancer in White Mice: A Histopathological Study. *Adv. Anim. Vet. Sci.* [Internet] 2023 [cited 2024 Nov 16];11. Available from: <http://researcherslinks.com/current-issues/Evaluation-Anticancer-Effect-Saussurea-costus-Root-Extract-Against/33/1/6297/html>
49. Chen Y, Shen J, Yuan M, Li H, Li Y, Zheng S, et al. Dehydrocostus lactone suppresses gastric cancer progression by targeting ACLY to inhibit fatty acid synthesis and autophagic flux. *J. Adv. Res.* [Internet] 2024; Available from: <https://www.sciencedirect.com/science/article/pii/S2090123224000407>
50. Elshabrawy A, Salem M, Ahmed F, Nabeeh A, Abdel-Wahhab K. The Therapeutic and Synergistic Effect of *Saussurea costus* Extract against Induced Leukemia in Adult Male Rats. *Egypt. Acad. J. Biol. Sci. C Physiol. Mol. Biol.* 2023;15:1-19.
51. Kumar R, Bhardwaj P, Soni M, Singh R, Choudhary S, Virmani N, et al. Modulation of mammary tumour progression using murine model by ethanol root extract of *Saussurea costus* (falc.) lipsch. *J. Ethnopharmacol.* 2024;319:117302.
52. Lin X, Peng Z, Fu X, Liu C, Xu Y, Ji W, et al. Volatile oil from *Saussurea lappa* exerts antitumor efficacy by inhibiting epithelial growth factor receptor tyrosine kinase-mediated signaling pathway in hepatocellular carcinoma. *Oncotarget* 2016;7:79761-73.
53. Abd-Elmegeed ASS, saad Abd-alrahman H, Mohamed AA, Ghaber BM. Biological properties and identification of some active ingredients in *Anastatica hierochuntica* and *Lepidium sativum*, grown in Egypt. *Int. J. Sci. Res. Arch.* 2023;10:435-45.
54. AlOubaidi LA. Study the anticancer effect of *Lepidium sativum* leaves extract on squamous cell carcinoma (CAL-27) cell lines. *J. Nat. Sci. Res.* 2014;4:48-52.
55. Amina M, Al Musayeib NM, Al-Hamoud GA, Al-Dbass A, El-Ansary A, Ali MA. Prospective of biosynthesized *L.sativum* oil/PEG/Ag-MgO bionanocomposite film for its antibacterial and anticancer potential. *Saudi J. Biol. Sci.* 2021;28:5971-85.
56. Basaiyye SS, Kashyap S, Krishnamurthi K, Sivanesan S. Induction of apoptosis in leukemic cells by the alkaloid extract of garden cress (*Lepidium sativum* L.). *J. Integr. Med.* 2019;17:221-8.
57. Efati Z, Shahangian SS, Darroudi M, Amiri H, Hashemy SI, Aghamaali MR. Green chemistry synthesized zinc oxide nanoparticles in *Lepidium sativum* L. seed extract and evaluation of their anticancer activity in human colorectal cancer cells. *Ceram. Int.* 2023;49:32568-76.
58. El-Haggar M, El-Hosseiny L, Ghazy NM, El-Fiky FK, El-Hawiet A. Phytochemical investigation, antimicrobial and cytotoxic activities of suspension cultures of *Lepidium sativum* L. *South Afr. J. Bot.* 2021;138:500-5.
59. Ibrahim MM, Mounier MM, Bekheet SA. Targeting apoptotic anticancer response with natural glucosinolates from cell suspension culture of *Lepidium sativum*. *J. Genet. Eng. Biotechnol.* 2023;21:53.
60. Indumathy R, Aruna A. Cytotoxic potential of various extracts of *Lepidium sativum* (Linn.). An in-vitro evaluation. *Int J Pharm Pharm Sc* 2015;2:1-5.
61. Jahani S, Heidari Z, Azami M, Moudi B. Comparison of Anticancer Effects of Hydroalcoholic Extracts of *Camellia sinensis* and *Lepidium sativum* L. on HeLa Cell Line. *Int. J. Cancer Manag.* [Internet] 2020 [cited 2024 Nov 16];13. Available from: <https://brieflands.com/articles/ijcm-98913.html>
62. Mahassni SH, Al-Reemi RM. Cytotoxic effect of an aqueous extract of *Lepidium sativum* L. seeds on human breast cancer cells. 2013;
63. Meer B, Andleeb A, Iqbal J, Ashraf H, Meer K, Ali JS, et al. Bio-Assisted Synthesis and Characterization of Zinc Oxide Nanoparticles from *Lepidium sativum* and Their Potent Antioxidant, Antibacterial and Anticancer Activities. *Biomolecules* 2022;12:855.
64. Nazir S, El-Sherif AA, Abdel-Ghani NT, Ibrahim MAA, Hegazy MEF, Atia MAM. *Lepidium sativum* Secondary Metabolites (Essential Oils): In Vitro and In Silico Studies on Human Hepatocellular Carcinoma Cell Lines. *Plants* 2021;10:1863.
65. Rajasekaran R, Suresh PK. Evaluation of Cell Death Potential of *Lepidium sativum* Seed Extracts in MCF-7 Cells and Molecular Docking-based Correlation of Identified Bioactive Components with Human Caspase-6 Protein. *Indian J. Pharm. Educ. Res.* 2022;56:166-74.
66. Selek S, Koyuncu I, Caglar HG, Bektas I, Yilmaz MA, Gonen A, et al. The evaluation of antioxidant and anticancer effects of *Lepidium Sativum* Subsp *Spinescens* L. methanol extract on cancer cells. *Cell. Mol. Biol.* 2018;64:72-80.
67. Alqahtani AS, Abdel-Mageed WM, Shahat AA, Parvez MK, Al-Dosari MS, Malik A, et al. Proanthocyanidins from the stem bark of *Rhus tripartita* ameliorate methylglyoxal-induced endothelial cell apoptosis. *J. Food Drug Anal.* 2019;27:758-65.
68. Ben Miled H, Saada M, Jallali I, Ben Barka Z, Tlili M, Alimi H, et al. Variability of antioxidant and biological activities of *Rhus tripartita* related to phenolic compounds. *EXCLI J.* 16Doc439 ISSN 1611-2156 [Internet] 2017 [cited 2024 Nov 10]; Available from: https://www.excli.de/vol16/Ben_Miled_31032017_proof.pdf
69. Rekek I, Ben Ameer R, Ayadi W, Soussi A, Gargouri A, Allouche N. Anti-oxidant, anti-diabetic and anti-lipidemic activities of root bark extracts from *Rhus tripartita* and cytotoxicity evaluation of isolated compounds. *South Afr. J. Bot.* 2022;147:71-80.
70. Tlili H, Macovei A, Buonocore D, Lanzafame M, Najjaa H, Lombardi A, et al. The polyphenol/saponin-rich *Rhus tripartita* extract has an apoptotic effect on THP-1 cells through the PI3K/AKT/mTOR signaling pathway. *BMC Complement. Med. Ther.* 2021;21:153.
71. Tlili H, Hanen N, Ben Arfa A, Neffati M, Boubakri A, Buonocore D, et al. Biochemical profile and in vitro biological activities of extracts from seven folk medicinal plants growing wild in southern Tunisia. *PLOS ONE* 2019;14:e0213049.
72. El-Hawary SS, El-Tantawi ME, Kirolos FN, Hammam WE. Chemical Composition, in Vitro Cytotoxic and Antimicrobial Activities of Volatile Constituents from *Pyrus communis* L. and *Malus domestica* Borkh. Fruits cultivated in Egypt. *J. Essent. Oil Bear. Plants* 2018;21:1642-51.
73. Kolniak-Ostek J, Kłopotowska D, Rutkowska KP, Skorupińska A, Kruczyńska DE. Bioactive Compounds and Health-Promoting Properties of Pear (*Pyrus communis* L.) Fruits. *Molecules* 2020;25:4444.
74. Hameed MF, Al-Shawi AAA. Phytochemical Analysis and Anticancer Evaluation of Iraqi Herb *Chenopodium Murale* Extracted by Microwave-assisted Extraction. 2021 [cited 2024 Nov 10]; Available from: <http://rgdoi.net/10.13140/RG.2.2.33581.20969>
75. Khalil HE, Ibrahim HIM, Ahmed EA, Emeka PM, Alhaidar IA. Orientin, a Bio-Flavonoid from *Trigonella hamosa* L., Regulates COX-2/PGE-2 in A549 Cell Lines via miR-26b and miR-146a. *Pharmaceutics* 2022;15:154.
76. Nasim N, Sandeep IS, Mohanty S. Plant-derived natural products for drug discovery: current approaches and prospects. *The Nucleus* 2022;65:399-411.
77. Lei Z, Tian Q, Teng Q, Wurlpel JND, Zeng L, Pan Y, et al. Understanding and targeting resistance mechanisms in cancer. *MedComm* 2023;4:e265.
78. Binobead MA, Aziz IM, Ibrahim SM, Aljowaie RM. Chemical composition and bioactivities of the methanol root extracts of *Saussurea costus*. *Open Chem.* 2024;22:20240002.
79. Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. *Target. Cell. Signal. Pathw.* 2022;85:253-75.
80. Cruceriu D, Baldasici O, Balacescu O, Berindan-Neagoe I. The dual role of tumor necrosis factor- α (TNF- α) in breast cancer: molecular insights and therapeutic approaches. *Cell. Oncol.* 2020;43:1-18.
81. El Sayed RAA, Hanafy ZEM, Abd El Fattah HF, Mohamed AK. Possible antioxidant and anticancer effects of plant extracts from *Anastatica hierochuntica*, *Lepidium sativum* and *Carica papaya* against Ehrlich ascites carcinoma cells. *Cancer Biol* 2020;10:1-16.
82. Pistrutto G, Trisciuglio D, Ceci C, Garufi A, D'Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. *Aging* 2016;8:603-19.
83. Li Q, Li Z, Luo T, Shi H. Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. *Mol. Biomed.* 2022;3:47.
84. Patel AA, Amanullah M, Elsaid FG, Soliman T, Eissa M, Alotheid H. In-Vitro evaluation of anti-cancer and genotoxic potential of medicinal herb *Saussurea lappa* extract in human cancer cell lines. *Eur. J. Mol. Clin. Med.* 2020;7.
85. Ansari S, Hasan K, Bhat S. Anticancer, antioxidant, and hepatoprotective activity of *Saussurea lappa*, C.B. clarke (qust) on human hepatoma cell line. *J. Cancer Res. Ther.* 2021;17:499-503.

86. Yang M, Zhang J, Li Y, Han X, Gao K, Fang J. Bioassay-guided isolation of dehydrocostus lactone from *Saussurea lappa*: A new targeted cytosolic thioredoxin reductase anticancer agent. *Arch. Biochem. Biophys.* 2016;607:20–6.
87. Okubo S, Ohta T, Fujita H, Shoyama Y, Uto T. Costunolide and dehydrocostuslactone from *Saussurea lappa* root inhibit autophagy in hepatocellular carcinoma cells. *J. Nat. Med.* 2021;75:240–5.
88. Peng Z, Wang Y, Fan J, Lin X, Liu C, Xu Y, et al. Costunolide and dehydrocostuslactone combination treatment inhibit breast cancer by inducing cell cycle arrest and apoptosis through c-Myc/p53 and AKT/14-3-3 pathway. *Sci. Rep.* 2017;7:41254.
89. Kumar R, Tripathi BN, Rana J, Bhardwaj P, Singla A, Asrani RK, et al. Prevention of DMBA-induced Mammary Tumors from Pulmonary Metastases by *Saussurea costus* (Falc.) Lipsch Root Ethanolic Extract in Sprague Dawley Rats. *Indian J. Anim. Res.* [Internet] 2024 [cited 2024 Nov 16]; Available from: <http://arcjournals.com/journal/indian-journal-of-animal-research/B-5170>
90. Zhang R, Hao J, Wu Q, Guo K, Wang C, Zhang WK, et al. Dehydrocostus lactone inhibits cell proliferation and induces apoptosis by PI3K/Akt/Bad and ERS signalling pathway in human laryngeal carcinoma. *J. Cell. Mol. Med.* 2020;24:6028–42.